We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Novavax (NVAX - Free Report) closed at $1.92, marking a +1.05% move from the previous day. This move outpaced the S&P 500's daily loss of 0.63%. Meanwhile, the Dow lost 0.43%, and the Nasdaq, a tech-heavy index, lost 1.04%.
Heading into today, shares of the vaccine maker had lost 9.95% over the past month, lagging the Medical sector's loss of 6.18% and the S&P 500's loss of 6.28% in that time.
Investors will be hoping for strength from NVAX as it approaches its next earnings release, which is expected to be November 6, 2018. In that report, analysts expect NVAX to post earnings of -$0.12 per share. This would mark year-over-year growth of 20%. Meanwhile, our latest consensus estimate is calling for revenue of $10.17 million, up 21.75% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.50 per share and revenue of $39.07 million, which would represent changes of +20.63% and +25.3%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for NVAX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.85% lower. NVAX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Gains As Market Dips: What You Should Know
In the latest trading session, Novavax (NVAX - Free Report) closed at $1.92, marking a +1.05% move from the previous day. This move outpaced the S&P 500's daily loss of 0.63%. Meanwhile, the Dow lost 0.43%, and the Nasdaq, a tech-heavy index, lost 1.04%.
Heading into today, shares of the vaccine maker had lost 9.95% over the past month, lagging the Medical sector's loss of 6.18% and the S&P 500's loss of 6.28% in that time.
Investors will be hoping for strength from NVAX as it approaches its next earnings release, which is expected to be November 6, 2018. In that report, analysts expect NVAX to post earnings of -$0.12 per share. This would mark year-over-year growth of 20%. Meanwhile, our latest consensus estimate is calling for revenue of $10.17 million, up 21.75% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.50 per share and revenue of $39.07 million, which would represent changes of +20.63% and +25.3%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for NVAX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.85% lower. NVAX is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.